- Home
- IKT vs NCZ Comparison
IKT vs NCZ Comparison
Compare IKT & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IKT | NCZ |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 282.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | IKT | NCZ |
|---|---|---|
| Price | $2.00 | $15.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 933.5K | 71.4K |
| Earning Date | 03-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.16% |
| EPS Growth | ★ 57.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $11.86 |
| 52 Week High | $2.27 | $15.68 |
Technical Indicators
Market Signals| Indicator | IKT | NCZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.27 | 73.89 |
| Support Level | $1.43 | $13.07 |
| Resistance Level | $2.10 | N/A |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 100.00 | 98.02 |
Price Performance
Historical ComparisonAbout IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.